Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats

Table 1 Weights, liver function tests, and cytokines.

	Controls	LPS	Anti-CD163-dexa plus LPS	High dexa plus LPS	Low dexa plus LPS
Body weight	199 ± 1	196 ± 2	207 ± 2g	204 ± 3	206 ± 3g
Weight loss	11 ± 1	14 ± 3	22 ± 2a	23 ± 2a	21 ± 1a
Spleen weight	465 ± 12	512 ± 31	492 ± 23	421 ± 11a	483 ± 23
ALT	42 ± 3	61 ± 16	57 ± 20	48 ± 9	77 ± 31
Bilirubin	3.0 ± 0.0	3.3 ± 0.3	3.1 ± 0.1	3.6 ± 0.4	4.0 ± 0.4
TNF-α	0 ± 0	26817 ± 9780a	7208 ± 1977a,c	16891 ± 4210a	21583 ± 7117a
IL-6	0 ± 0	23075 ± 6758a	15685 ± 3779a,c,e	32964 ± 8294a	25715 ± 4036a

Body weight (g), body weight loss (g), spleen weight (mg), plasma alanine aminotransferase (U/L), and bilirubin (μmol/L) in controls (n = 8) and in animals injected with LPS 24 h after vehicle (n = 8), anti-CD163mAb-dexa (n = 8), high dose (n = 8) and low dose (n = 8) dexamethasone at termination of study. Plasma TNF-α (pg/mL) and IL-6 (pg/mL) are measured 2 h after saline (controls) or LPS injection.

^aP < 0.05 vs controls;

^cP < 0.05 vs low dose free dexamethasone group;

^eP < 0.05 vs high dose free dexamethasone group;

^gP < 0.05 vs vehicle. ALT: Alanine aminotransferase; TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6; LPS: Lipopolysaccharide.